Bringing Colorectal Cancer screening to your employees.
If you knew there was a simple blood draw that could potentially save lives, would you want to bring it to your workforce? What if that cancer screening took place onsite, and many of the workflows and logistics were handled?
Introducing Shield from Guardant Health, a colorectal cancer screening that consists of a simple blood draw. Colorectal Cancer is the 3rd most common cancer in the U.S. We will work with you on the best way to offer Shield and integrate a screening program. An easier way to screen for colorectal cancer. No preparation time. No sedation. Less time away from work.
Learn more
52% of the screening-eligible, working-age population aged 45-64 is not compliant with guideline-recommended screening.
33M average-risk people aged 45-64 are not up-to-date with CRC screening.
Estimates based on ACS 2018 (BRFSS)1
Early detection saves lives.
- Colorectal Cancer (CRC) remains the second-leading cause of cancer-related deaths in the United States.2
- 60% of colorectal cancer deaths could be prevented with regular screening.3
- CRC screening compliance rates remain low despite current screening options offered.4
- The five-year survival rate based on stage of diagnosis is 90% for early-stage (I-II) vs. 14% for late-stage (IV)5
Early detection of Colorectal Cancer is critical.
5-YEAR SURVIVAL RATE
Based on stage of Diagnosis5
Your employee's health is a critical investment.
Early-stage diagnosis also leads to lowered treatment costs.
Cost of Colorectal Cancer early-stage vs late-stage
CRC impacts more than just your employees.
A CRC diagnosis could lead to substantial work loss, which can cost your organization millions.6
As an employer, you have an opportunity to help contribute to the health of your employees by empowering them to get screened and take control of their health.
Shield™ is a blood-based test that requires no preparation time and less time away from work
-
Simple blood draw
-
Sample sent to Guardant Health Laboratory
-
Receive results within two weeks
How Shield Works:
Shield detects cancer signals in the blood by looking for DNA and other markers shed by tumors.*
*The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods.
Patients with an abnormal blood-based screening result should be referred for colonoscopic evaluation.
Studies suggest that Shield would dramatically improve CRC detection compared to other screening tests.
Blood-based CRC screening with 90% compliance far exceeds traditional screening methods:
How we will work with you:
1. Identify
Pinpoint current screening situation and benchmarks
2. Determine
Decide best screening program and develop process
3. Educate
Provide awareness and recruitment materials
4. Implement
Conduct screening activities
5. Report
Results reported to employee
6. Assess
Collect data and evaluate program
We’ll meet your employees where they are.
Whether it’s through your worksite health center or through an onsite screening program, Guardant Health will partner with you to help screen your employees.
Closing the gap and redefining colorectal cancer screening
With more than 10,000 tests completed since Shield launched in 2022, more and more individuals are beginning to see the benefits. In fact, Shield demonstrated 90% compliance in real-world clinical settings.11,12*
*Compliance rate for the first 8,000 patients that were prescribed Shield and completed it.
Setting you up for success
From educational materials to blood collection kits, we will provide you with the tools and resources you need.
Guardant Health resources
Digital tool kit for education awareness and marketing
Pre-qualifying questionnaires and guidelines
Blood collection kits
Phlebotomy and telehealth ordering providers for onsite screening events*
Other resources like patient navigation
*Services provided by an independent third-party contracted by Guardant Health
FAQs
Yes. 83% of eligible patients who refused colonoscopy preferred a blood-based approach over stool tests.*
*Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy inGermany. BMC Gastroenterol. 2014;14:183. doi:10.1186/1471-230X-14-183
Many people put off getting screened because of the time constraints, the inconvenience of bowel prep and sedation required for a procedure like a colonoscopy, or the disgust of handling a stool test. This is valuable time lost when early detection is important. Shield is a validated test in a large prospective cohort and employers support screening for their population. It’s non-invasive and requires no extra prep time, dietary constraints or sedation. This makes Shield an attractive option for some.
Everyone aged 45-75 should be screened. If you have family history or other personal history of bowel disease or cancer talk to your healthcare provider to discuss your screening options.
People are considered at average risk if:
- They are 45 years of age or older
- There is no family history of colorectal cancer
- There is no personal history of colorectal cancer or certain types of polyps
- There is no confirmed or suspected hereditary colorectal cancer syndrome
- There is no personal history of inflammatory bowel disease (ulcerative colitis or Crohn’s disease)
For additional questions, contact us at GetScreened@GuardantHealth.com.
About 
At Guardant Health, we’re dedicated to the belief that precision oncology has the extraordinary power to improve patient outcomes. By looking at the unique dimensions of cancer found in blood, including genomic alterations, methylation, and fragmentomics, we are unlocking insights that can increasingly help patients across all stages of cancer – including at its earliest, when it’s most treatable.
By partnering with Guardant Health, you can help your employees access the latest advancements that can ensure the best outcomes for them—and potentially help reduce cancer treatment costs for your organization.
Learn how Shield fits into your organization
Please fill out the information below or email us directly and we will be in touch!
- The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
- Patients with an “abnormal signal detected” Shield result should be referred for colonoscopic evaluation
- A “normal signal detected” Shield result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
- Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
